Icotrokinra, an oral IL-23R antagonist peptide, gains US FDA approval for moderate-to-severe plaque psoriasis
Icotrokinra: First Approval.
Abstract
Oral peptide Icotrokinra received US FDA approval in March 2026 for moderate-to-severe plaque psoriasis in adults and pediatric patients ≥ 12 years and ≥ 40 kg.